Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran

被引：20

作者：

Ross, Stephanie ^{[1
]}

Pare, Guillaume ^{[1
,2
,3
,4
,5
]}

机构：

[1] McMaster Univ, Populat Hlth Res Inst, DB CVSRI, Hamilton, ON L8L 2X2, Canada

[2] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8L 2X2, Canada

[3] McMaster Univ, Dept Clin Epidemiol & Biostat, Populat Genom Program, Hamilton, ON L8L 2X2, Canada

[4] Hamilton Hlth Sci, Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada

[5] McMaster Univ, Hamilton, ON L8L 2X2, Canada

来源：

PHARMACOGENOMICS | 2013年 / 14卷 / 13期

关键词：

clopidogrel; dabigatran; pharmacogenetic; warfarin; ACUTE CORONARY SYNDROMES; PLATELET RESPONSE; CYP2C19; GENOTYPE; GENETIC-VARIANTS; CARDIOVASCULAR OUTCOMES; RANDOMIZED EVALUATION; ATRIAL-FIBRILLATION; THROMBIN INHIBITOR; P-GLYCOPROTEIN; POLYMORPHISMS;

D O I：

10.2217/pgs.13.149

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Genetic polymorphisms are thought to contribute to the wide intraindividual variability in antiplatelet and anticoagulant drug response. Pharmacogenetics is the study of how genetic variants influence drug response and how the adoption of a more personalized approach in antiplatelet and anticoagulant therapy may help to minimize harmful drug effects and optimize care for individual patients. However, due to sometimes conflicting evidence, the uptake of pharmacogenetics in the clinical setting has been slow. In this article, we review the genetic mechanisms contributing to the variability in response to three commonly used and emerging antiplatelet and anticoagulant drug therapies, namely clopidogrel, warfarin and dabigatran. We will focus on common genetic variants that influence the absorption, metabolism and/or action of these agents, including CYP2C19 (*2, *3 and *17), CYP3A4, CYP3A5, CYP2C9, ABCB1, P2RY12, CYP2C9 (*2/*3), VKORC1 and CESI.

引用

页码：1565 / 1572

页数：8

共 61 条

[1] The pharmacogenetics of antiplatelet agents: towards personalized therapy? [J].

Ahmad, Tariq ;

Voora, Deepak ;

Becker, Richard C. .

NATURE REVIEWS CARDIOLOGY, 2011, 8 (10) :560-571

[2] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].

Aithal, GP ;

Day, CP ;

Kesteven, PJL ;

Daly, AK .

LANCET, 1999, 353 (9154) :717-719

[3] A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy [J].

Avery, P. J. ;

Jorgensen, A. ;

Hamberg, Ak ;

Wadelius, M. ;

Pirmohamed, M. ;

Kamali, F. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (05) :701-706

[4] The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study [J].

Bhatt, Deepak L. ;

Pare, Guillaume ;

Eikelboom, John W. ;

Simonsen, Katy L. ;

Emison, Eileen S. ;

Fox, Keith A. A. ;

Steg, Ph Gabriel ;

Montalescot, Gilles ;

Bhakta, Nihar ;

Hacke, Werner ;

Flather, Marcus D. ;

Mak, Koon-Hou ;

Cacoub, Patrice ;

Creager, Mark A. ;

Berger, Peter B. ;

Steinhubl, Steven R. ;

Murugesan, Gurunathan ;

Mehta, Shamir R. ;

Kottke-Marchant, Kandice ;

Lincoff, A. Michael ;

Topol, Eric J. .

EUROPEAN HEART JOURNAL, 2012, 33 (17) :2143-2150

[5] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel [J].

Brandt, J. T. ;

Close, S. L. ;

Iturria, S. J. ;

Payne, C. D. ;

Farid, N. A. ;

Ernest, C. S., II ;

Lachno, D. R. ;

Salazar, D. ;

Winters, K. J. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) :2429-2436

[6] CYP4F2 genetic variant alters required warfarin dose [J].

Caldwell, Michael D. ;

Awad, Tarif ;

Johnson, Julie A. ;

Gage, Brian F. ;

Falkowski, Mat ;

Gardina, Paul ;

Hubbard, Jason ;

Turpaz, Yaron ;

Langaee, Taimour Y. ;

Eby, Charles ;

King, Cristi R. ;

Brower, Amy ;

Schmelzer, John R. ;

Glurich, Ingrid ;

Vidaillet, Humberto J. ;

Yale, Steven H. ;

Zhang, Kai Qi ;

Berg, Richard L. ;

Burmester, James K. .

BLOOD, 2008, 111 (08) :4106-4112

[7] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[8] Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome [J].

Cuisset, Thomas ;

Frere, Corinne ;

Quilici, Jacques ;

Morange, Pierre-Emmanuel ;

Saut, Noemie ;

Lambert, Marc ;

Camoin, Laurence ;

Vague, Irene Juhan ;

Bonnet, Jean-Louis ;

Alessi, Marie-Christine .

THROMBOSIS RESEARCH, 2007, 120 (06) :893-899

[9] CYP2C19*2 and*17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome [J].

Cuisset, Thomas ;

Loosveld, Marie ;

Morange, Pierre Emmanuel ;

Quilici, Jacques ;

Moro, Pierre Julien ;

Saut, Noemie ;

Gaborit, Benedicte ;

Castelli, Christel ;

Beguin, Shirley ;

Grosdidier, Charlotte ;

Fourcade, Laurent ;

Bonnet, Jean-Louis ;

Alessi, Marie-Christine .

JACC-CARDIOVASCULAR INTERVENTIONS, 2012, 5 (12) :1280-1287

[10] A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J].

D'Andrea, G ;

D'Ambrosio, RL ;

Di Perna, P ;

Chetta, M ;

Santacroce, R ;

Brancaccio, V ;

Grandone, E ;

Margaglione, M .

BLOOD, 2005, 105 (02) :645-649

← 1 2 3 4 5 6 7 →